Literature DB >> 3494426

Comparison of histologic and quantitative techniques in evaluation of therapy for experimental Pneumocystis carinii pneumonia.

C K Kim, J M Foy, M T Cushion, D Stanforth, M J Linke, H L Hendrix, P D Walzer.   

Abstract

Pneumocystis carinii pneumonia was induced in rats by the administration of corticosteroids, and histologic and quantitative techniques were compared in the evaluation of the severity of the disease and response to therapy. A highly significant correlation was found between the histologic score of the extent of alveolar involvement (the standard method of assessment) and the number of P. carinii cysts and nuclei in lung homogenates, lung weight, and lung weight/body weight ratio. Clear differences were noted between rats which responded well and rats which responded poorly to therapy by all techniques. Quantitation of P. carinii cysts and nuclei revealed a 10(4)-fold reduction in organism burden with successful treatment. Thus, these techniques should be helpful in the development of testing of new antimicrobial agents in the rat model of pneumocystosis.

Entities:  

Mesh:

Year:  1987        PMID: 3494426      PMCID: PMC174691          DOI: 10.1128/AAC.31.2.197

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Delayed development of pneumocystis pneumonia following administration of short-term high-dose trimethoprim-sulfamethoxazole.

Authors:  L J Wolff; R L Baehner
Journal:  Am J Dis Child       Date:  1978-05

2.  Techniques for examining Pneumocystis carinii in fresh specimens.

Authors:  J J Ruffolo; M T Cushion; P D Walzer
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

3.  Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features.

Authors:  P D Walzer; D P Perl; D J Krogstad; P G Rawson; M G Schultz
Journal:  Ann Intern Med       Date:  1974-01       Impact factor: 25.391

4.  Latent Pneumocystis infection of rats, relapse, and chemotherapy.

Authors:  J K Frenkel; J T Good; J A Shultz
Journal:  Lab Invest       Date:  1966-10       Impact factor: 5.662

5.  Combination of pentamidine and trimethoprim-sulfamethoxazole in therapy of Pneumocystis carinii pneumonia in rats.

Authors:  R M Kluge; D M Spaulding; A J Spain
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

6.  Growth characteristics and pathogenesis of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; R D Powell; K Yoneda; M E Rutledge; J E Milder
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

7.  Lung weight parallels disease severity in experimental coccidioidomycosis.

Authors:  M Huppert; S H Sun; I Gleason-Jordon; K R Vukovich
Journal:  Infect Immun       Date:  1976-12       Impact factor: 3.441

8.  Limited effect of trimethoprim-sulfamethoxazole prophylaxis on Pneumocystis carinii.

Authors:  W T Hughes
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

9.  Failure of pentamidine isethionate to provide chemoprophylaxis against Pneumocytis carinii infection in rats.

Authors:  K A Western; L Norman; A G Kaufmann
Journal:  J Infect Dis       Date:  1975-03       Impact factor: 5.226

10.  Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; P C McNabb; T D Makres; S Feldman
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

View more
  26 in total

1.  Quantification and assessment of viability of Pneumocystis carinii organisms by flow cytometry.

Authors:  S E Lapinsky; D Glencross; N G Car; J M Kallenbach; S Zwi
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

2.  Furazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J Foy; J L Zhang
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

3.  Guanylhydrazones in therapy of Pneumocystis carinii pneumonia in immunosuppressed rats.

Authors:  P D Walzer; J Foy; J Runck; P Steele; M White; R S Klein; B A Otter; R J Sundberg
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

4.  Use of semiquantitative PCR to assess onset and treatment of Pneumocystis carinii infection in rat model.

Authors:  T J O'Leary; M M Tsai; C F Wright; M T Cushion
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

5.  Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.

Authors:  P D Walzer; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

6.  New rat model of Pneumocystis pneumonia induced by anti-CD4(+) T-lymphocyte antibodies.

Authors:  Timothy D Thullen; Alan D Ashbaugh; Kieran R Daly; Michael J Linke; Paul E Steele; Peter D Walzer
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

7.  Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J Foy; M J Linke; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

8.  Regulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat.

Authors:  W R Rice; F M Singleton; M J Linke; P D Walzer
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

9.  Comparative study of antipneumocystis agents in rats by using a Pneumocystis carinii-specific DNA probe to quantitate infection.

Authors:  P A Liberator; J W Anderson; M Powles; L A Pittarelli; M Worley; M Becker-Hapak; D C Graves; D M Schmatz
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

10.  Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat.

Authors:  S A Theus; R P Andrews; P Steele; P D Walzer
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.